SEARCH

SEARCH BY CITATION

References

  • 1
    Buckwalter JA, Stanish WD, Rosier RN, Schenck RC Jr, Dennis DA, Coutts RD. The increasing need for nonoperative treatment of patients with osteoarthritis. Clin Orthop Relat Res 2001; 385: 3645.
  • 2
    Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 15631566.
  • 3
    Tegeder I, Muth-Selbach U, Lötsch J, Rüsing G, Oelkers R, Brune K, Meller S, Kelm GR, Sörgel F, Geisslinger G. Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Clin Pharmacol Ther 1999; 65: 357368.
  • 4
    Miyatake S, Ichiyama H, Kondo E, Yasuda K. Randomized clinical comparisons of diclofenac concentration in the soft tissues and the blood plasma between topical and oral applications. Br J Clin Pharmacol 2009; 67: 125129.
  • 5
    Brogden RN, Heel RC, Speight TM, Avery GS. Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases. Drugs 1979; 18: 417438.
  • 6
    Buchanan WW, Kassam YB. European experience with flurbiprofen. A new analgesic/anti-inflammatory agent. Am J Med 1986; 80: 145152.
  • 7
    Bolten W. The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbiprofen LAT. Br J Clin Pract 1994; 48: 190195.
  • 8
    Fujita M, Kobayashi H. A pharmacokinetic study of Zepolas® tape (Japanese text). Med Cons New-Remed (ISSN 0037-380X) 2011; 48: 11481152.
  • 9
    Medicine Interview Form of Froben® Tablet 40. Revised by Kaken Pharmaceutical Co. LTD in February 2011 (Version 7). Opened in the Website of Pharmaceuticals and Medical Devices Agency, Japan. Available at http://www.info.pmda.go.jp/ (last accessed 1 December 2011).
  • 10
    Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28: 100114.
  • 11
    Cardoe N, de Silva M, Glass RC, Risdall PC. Serum concentrations of flurbiprofen in rheumatoid patients receiving flurbiprofen over long periods of time. Curr Med Res Opin 1977; 5: 2125.
  • 12
    Smith IJ, Hinson JL, Johnson VA et al. Flurbiprofen in postpartum women: plasma and breast milk disposition. J Clin Pharmacol 1989; 29: 174184.
  • 13
    Knadler MP, Brater DC, Hall SD. Stereoselective disposition of flurbiprofen in uraemic patients. Br J Clin Pharmacol 1992; 33: 377383.
  • 14
    Geisslinger G, Lotsch J, Menzel S, Kobal G, Brune K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol 1994; 37: 392394.
  • 15
    Aniimov YG, Roberts MS. Modeliing dermal drug distribution after topical application in human. Pharm Res 2011; 28: 21192129.
  • 16
    Sammeta SM, Murthy SN. ‘ChilDrive’. A technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. Pharm Res 2009; 26: 25352540.
  • 17
    Capell HA, Konetschnik B, Glass RC. Anti-inflammatory analgesic drug responders and non-responders: a clinicopharmacological strudy of flurbiprofen. Br J Clin Pharmacol 1977; 4: 623624.
  • 18
    Huskisson EC, Scott PJ, Boyle S, Patrick M. Flurbiprofen at night. Curr Med Res Opin 1977; 5: 8587.